This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (8)  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Social Bookmarking   What's this?

A New Aminoglycoside Antibiotic

Donald O. Schiffman, PhD

JAMA. 1977;238(14):1547-1550.

Abstract
Amikacin sulfate, the first semisynthetic aminoglycoside antibiotic introduced in this country, is resistant to the bacterial enzymes that specifically inactivate kanamycin sulfate, gentamicin sulfate, and tobramycin sulfate. This agent is potentially effective, therefore, against many serious infections caused by Gram-negative organisms resistant to other aminoglycosides. It appears to be similar to gentamicin in its in vitro spectrum, in clinical applications, and in the incidence and severity of adverse reactions reported. Like the other drugs in this class, amikacin can cause renal and otic toxic reactions.

(JAMA 238:1547-1550, 1977)

Author Affiliations
Dr Schiffman is Senior Scientist, AMA Department of Drugs. This communication was prepared with the assistance of consultants.

Footnotes
Scientific data on amikacin sulfate were supplied by Bristol Laboratories, Syracuse, NY.

Reprint requests to the Department of Drugs, American Medical Association, 535 N Dearborn St, Chicago, IL 60610.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Empiric Therapy for Infections in Granulocytopenic Cancer Patients: Continuous Infusion of Amikacin Plus Cephalothin
Feld et al.
Arch Intern Med 1979;139:310-314.
ABSTRACT